Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
01
09
2020
revised:
02
12
2020
accepted:
24
12
2020
pubmed:
3
1
2021
medline:
22
1
2022
entrez:
2
1
2021
Statut:
ppublish
Résumé
Inflammatory diseases are believed to develop as a result of dysregulated inflammatory responses to environmental factors on susceptible genetic backgrounds. Operating at the level of post-transcriptional gene regulation, miRNAs are a class of endogenous, small noncoding RNAs that can promote downregulation of protein expression by translational repression and/or mRNA degradation of target mRNAs involved in inflammation. MiR-124 is a crucial modulator of inflammation and innate immunity that could provide therapeutic restitution of physiological pathways lost in inflammatory diseases. A recently discovered small quinoline, ABX464, was shown to upregulate miR-124 in human immune cells. In vivo, in a proof-of-concept clinical study, ABX464 showed robust and consistent efficacy in ulcerative colitis (UC). In this review, we examine the current therapeutic options proposed for UC and discuss the drug candidate ABX464 in this context.
Identifiants
pubmed: 33387693
pii: S1359-6446(20)30537-7
doi: 10.1016/j.drudis.2020.12.019
pii:
doi:
Substances chimiques
ABX464
0
Immunologic Factors
0
MIRN124 microRNA, human
0
MicroRNAs
0
Quinolines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1030-1039Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.